scispace - formally typeset
R

Rebecca L. Fouts

Researcher at Eli Lilly and Company

Publications -  8
Citations -  800

Rebecca L. Fouts is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Arthritis & Protein kinase C. The author has an hindex of 8, co-authored 8 publications receiving 792 citations.

Papers
More filters
Journal ArticleDOI

Increased Protein Kinase C Activity and Expression of Ca2+-Sensitive Isoforms in the Failing Human Heart

TL;DR: In failed human heart, PKC-beta1 and -beta2 expression and contribution to total PKC activity are significantly increased, which may signal a role for Ca2+-sensitive PKC isoforms in cardiac mechanisms involved in heart failure.
Journal ArticleDOI

Decreased p38 MAPK Activity in End-Stage Failing Human Myocardium: p38 MAPK α is the Predominant Isoform Expressed in Human Heart

TL;DR: The correlation between decreased MAPKAPK-2 phosphorylation and loss of active p38MAPK in failing human myocytes suggests that decreases in the activation of p38 MAPK alpha, the predominant cardiac isoform, occur prior to end-stage heart failure.
Journal ArticleDOI

Protein Kinase C- α and - ϵ Modulate Connexin-43 Phosphorylation in Human Heart

TL;DR: In the human heartPKC- alpha, PKC- epsilon, and Cx-43 appear to form a closely associated complex, with PKC activity significantly above endogenous levels in the co-immunoprecipitated CX-43 complexes.
Journal ArticleDOI

Evaluation of the effects of various anti-arthritic drugs on type II collagen-induced mouse arthritis model

TL;DR: The type II collagen-induced mouse arthritis model may not be highly suitable for detection of the traditional nonsteroidal anti-inflammatory class of drugs or the anti-rheumatic drugs, although the possibility remains that some new and novel immunosuppressive agents may be detected with this model.
Journal ArticleDOI

The effect of a selective estrogen receptor modulator on the progression of spontaneous autoimmune disease in MRL lpr/lpr mice.

TL;DR: In this article, female MRL lpr / lpr mice have been dosed po daily for 7 months with the selective estrogen receptor modulator (SERM) LY139478 or 17α-ethinylestradiol (EE2, 1 mg/kg) and compared to vehicle control animals.